Molecular Imaging and Contrast Agent Database adds 15 agents

Molecular Imaging and Contrast Agent Database (MICAD) has added 15 molecular imaging and contrast agents, totaling 913 agents in the MICAD database.

The new PET agents are:
  • anti-3-[18F]FACBC which targets L-type amino acid transporter;
  • [18F]FP-(+)-DTBZ ([18F]AV-133) which targets type 2 vesicular monoamine transporter (VMAT2);
  • [18F]7c which targets beta-amyloid;
  • [18F]PipISB which targets cannabinoid CB1 receptors;
  • [11C]DTBZ which targets type 2 vesicular monoamine transporter (VMAT2);
  • [11C]PipISB which targets cannabinoid CB1 receptors;
  • [64Cu]-AmBaSar-RGD which targets alpha v beta 3 integrin;
  • [64Cu]-AmBaSar which is non-targeted;
  • 68Ga-DOTA-Lys40-exendin-3 which targets glucagon-like peptide-1 receptor (GLP-1R);
  • 68Ga-DOTA-ZHER2:342-pep2 which targets epidermal growth factor receptor (HER2); and
  • 86Y-CHX-A''-DTPA-cetuximab which targets epidermal growth factor receptor (HER1).

The new SPECT agents are:
  • 111In-DTPA-Lys40-exendin-3 which targets glucagon-like peptide-1 receptor (GLP-1R); and
  • [99mTc]5 which targets carbonic anhydrase IX.

The new optical agent is:
  • IR-783 which targets lysosomes and mitochondria.

The new multimodality agent is: 
  • Cy5.5-CNP-Gd(III) which is non-targeted.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.